← All cohorts · Borrelia burgdorferi (Lyme disease) cohorts
Johns Hopkins SLICE early-Lyme cohort (Aucott/Rebman)
source record (JSON) · schema v2.0.0 · CC BY 4.0
Design notes & limitations. Prospective inception cohort of ideally-treated early Lyme disease with a non-Lyme comparison group and a bio-repository, designed specifically to estimate the incidence of post-treatment Lyme disease. Functionally-impairing persistent symptoms occurred in 14% of treated patients vs 4% of controls, giving a rigorous denominator for PTLD that most Lyme literature lacks.
Identity & trigger
- Cohort id
aucott-slice-ptlds- Aliases
- Study of Lyme Immunology and Clinical Events (SLICE)
- Outbreak / event
- n/r
- Pathogen
- Borrelia burgdorferi (Lyme disease) (Bacterium)
- Exposure ascertainment
- clinical diagnosis
Design
- Design
- Prospective (inception)
- Denominator defined
- Yes
- Denominator method
- Patients with physician-diagnosed early Lyme disease (erythema migrans), ideally treated, enrolled at diagnosis; a group of endemic-area participants without Lyme disease serves as the comparison.
- Recruitment
- outpatient clinic
- Time zero
- Diagnosis and antibiotic treatment of early Lyme disease (week)
- Control group
- Healthy convenience
Size & attrition
- Enrolled
- 234
- Analysed / enrolled
- 234/234 (100%)
- Max follow-up (months)
- 12
Biospecimens
- Specimens
- Yes
- Types
- serum, plasma, pbmc
- Acute-phase specimens
- Yes
- Biobank
- active
- External access
- collaboration only
Observations (1)
Functional outcomes
14% Proportion
- Measure
- Impaired quality of life func:qol-impairment
- As worded
- “functionally-impairing persistent symptoms (post-treatment Lyme disease) after ideal treatment of early Lyme disease vs non-Lyme controls”
- Population
- whole cohort · denominator Assessed at timepoint · N=n=234
- Timing
- 12 mo (6-12 mo) · ref Not reported
- Method
- Unclear · Short Form-36 Health Survey
- Comparator
- Healthy convenience: 4%
- Comparability signature
- 662d1f3667 — measure func:qol-impairment · Unclear · ref Not reported · denom Assessed at timepoint · 6-12 mo · Proportion
- Provenance
- Results (14% of treated Lyme patients vs 4% of controls) · Manual · verified OSMF research-tracker (web-verified against source) on 2026-07-20
Publications
- Aucott JN, Yang T, Yoon I, Powell D, Geller SA, Rebman AW. (2022). Risk of post-treatment Lyme disease in patients with ideally-treated early Lyme disease: a prospective cohort study. International Journal of Infectious Diseases. DOI 10.1016/j.ijid.2022.01.033 primary
Provenance & verification
- Registration
- n/r
- Funders
- National Institutes of Health (NIAID), Steven & Alexandra Cohen Foundation
- Related cohorts
- none
- Symptom-inventory scope
- Targeted panel
- Last verified
- 2026-07-20 — OSMF research-tracker (web-verified against source)